Pharmacology and Toxicology of Methamphetamine Abuse (K05 DA00378)

描述（由申请人提供）：这是格伦·汉森博士高级科学家奖的竞争性更新申请。汉森博士是药学系的终身教授。托克斯&。他在药物滥用研究方面有20多年的经验，对我们理解精神兴奋剂对大脑单胺能系统和神经肽系统的短期和长期影响做出了重要贡献。汉森博士的K05奖（从1998年开始）使他从繁重的教学和委员会责任中解脱出来，使汉森博士能够将他75%的专业时间用于药物滥用/成瘾研究相关的努力。他的K05奖支持的活动产生了：(i)约57篇同行评议的科学出版物；在科学会议上提出的90篇摘要；（iii）被任命为NIDA神经科学和行为研究部主任（2000-2001）；（iv）担任国家药物滥用研究所代理所长（2001-2003年）；(v)被任命为犹他州戒毒中心主任（2003年至今）；（vi）成为NIDA主任的高级顾问（2003年至今）。更新汉森博士的K05将允许他指导研究以测试以下主要假设：(i)纹状体-黑神经通路的功能输出通过低剂量的甲基苯丙胺而增加，而不受高剂量甲基苯丙胺的影响；（ii）囊泡单胺转运体-2急性反应中第二组分的表达，而不是第一组分的表达与苯乙胺诱导的单胺神经毒性的发生有关；（iii）青少年黑质纹状体多巴胺通路对甲基苯丙胺诱导的神经毒性的难治性存在相关的基本机制；之前进行;还有宽容，老鼠。继续他的K05将使他能够在技术方面发展专业知识，这将大大促进他的研究工作，例如：(i)亚细胞分离；（ii） Western blotting和免疫沉淀蛋白表征；（三）转盘电极伏安法；（四）自我管理应急模式。除了研究项目，K05的支持将允许汉森博士直接努力创建跨学科研究团队进行药物滥用和转化研究。最后，该奖项将允许汉森博士继续指导本科生，研究生，博士后和年轻教师水平的缺乏经验的研究人员，以帮助他们的科学发展。

DESCRIPTION (provided by applicant): This is a competitive renewal application for Dr. Glen Hanson's Senior Scientist Award. Dr. Hanson is a tenured professor in the Department of Pharmacol. & Tox. at the University of Utah with more than 20 years experience in drug abuse research resulting in important contributions to our understanding of the short- and long-term effects of psychostimulants on brain monoaminergic and neuropeptide systems. Dr. Hanson's K05 award (beginning in 1998) has relieved him from heavy teaching and committee responsibilities, allowing Dr. Hanson to devote > 75% of his professional time to substance abuse/addiction research-related endeavors. Activities supported by his K05 award resulted in: (i) ~57 peer-reviewed scientific publications; (ii) >90 abstracts presented at scientific meetings; (iii) an appointment as the director of NIDA's Division of Neuro-science and Behavioral Research (2000-2001); (iv) becoming the acting Director of the National Institute on Drug Abuse (2001-2003); (v) an appointment as the director of the Utah Addiction Center (2003-present); and (vi) becoming a senior advisor to the director of NIDA (2003-present). Renewal of Dr. Hanson's K05 will permit him to direct research to test the following principal hypotheses: (i) the functional output of the striato-nigral pathway is increased by administration of low doses of methamphtamine and unaffected by administration of high doses of this drug; (ii) expression of a 2nd , but not the 1st , component of an acute response of the vesicular monoamine transporter-2 is linked to the occurrence of phenylethylamine-induced monamine neurotoxicity; and (iii) there are related mechanisms fundamental to the refractoriness of the nigrostriatal dopamine pathway to methamphetamine-induced neurotoxicity in: adolescent; previously lesioned; and tolerant, rats. Continuation of his K05 will allow Dr. Hanson to develop expertise in technologies that will substantially further his research efforts, such as: (i) subcellular fractionation; (ii) Western blotting and immunoprecipitation protein characterization; (iii) rotating disk electrode voltammetry; and (iv) self-administration contingency paradigms. In addition to research projects, the K05 support will allow Dr. Hanson to direct efforts to create interdisciplinary research teams to conduct drug abuse and translational research. Finally, this award will permit Dr. Hanson to continue mentoring inexperienced researchers at the under-graduate, graduate, postdoctoral and young faculty levels, to assist them in their scientific development.